Mordechai Elgrabli - Rekah Pharmaceutical CEO Director

All Insiders . Israel . 
Stock . Rekah Pharmaceutical Industry . Stakeholders . Insider . Mordechai Elgrabli
REKA Stock  ILA 1,499  110.00  7.92%   

Insider

Mordechai Elgrabli is CEO Director of Rekah Pharmaceutical Industry
Age 79
Phone972 3 558 1233
Webhttps://www.rekah.co.il

Rekah Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0222 %, meaning that it generated $0.0222 on every $100 dollars invested by stockholders. Rekah Pharmaceutical's management efficiency ratios could be used to measure how well Rekah Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Rekah Pharmaceutical Industry has accumulated 101.23 M in total debt with debt to equity ratio (D/E) of 1.01, which is about average as compared to similar companies. Rekah Pharmaceutical has a current ratio of 1.95, which is within standard range for the sector. Debt can assist Rekah Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Rekah Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rekah Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rekah to invest in growth at high rates of return. When we think about Rekah Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Eran NirKamada
50
Yifat EsqKamada
46
Thomas BardorAshot Ashkelon Industries
N/A
Tali PedhazurZuriPCB Tec
53
Yaela HagaiLeviUnitronics
51
Sasson DarvishBet Shemesh Engines
60
Tomer DvashPCB Tec
43
Boaz KarmyUnitronics
57
Lilach ZingerPCB Tec
49
Ivgeny BlokhUnitronics
N/A
Hanni NehemanKamada
53
Lilach TopilskyKamada
N/A
Jeff SerranoPCB Tec
N/A
Ariella RabanKamada
47
Albert BetzUnitronics
N/A
Reuven AvniPCB Tec
52
Ari ShamissKamada
N/A
Avishai RazBet Shemesh Engines
63
Efrat ShananBet Shemesh Engines
52
Ron AlkalaiUnitronics
53
Itzhak HaiUnitronics
55
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people. Rekah Pharmaceutical Industry (REKA) is traded on Tel Aviv Stock Exchange in Israel and employs 399 people.

Management Performance

Return On Equity0.0222
Return On Asset0.0208

Rekah Pharmaceutical Leadership Team

Elected by the shareholders, the Rekah Pharmaceutical's board of directors comprises two types of representatives: Rekah Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rekah. The board's role is to monitor Rekah Pharmaceutical's management team and ensure that shareholders' interests are well served. Rekah Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rekah Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Yuval Elgrabli, Deputy Devel
Yuval CPA, Chief Officer
Jacob Elgrably, Chief Shalpharm
Chaim Cohen, Chief Officer
Jack Azran, Chief Technologies
Yaakov Elgrabli, Chief Ltd
Georgette Elgrabli, Director Director
Meir Melumad, Director Operations
Mordechai Elgrabli, CEO Director

Rekah Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rekah Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0222
Return On Asset0.0208
Profit Margin0.01 %
Operating Margin0.05 %
Current Valuation316.92 M
Shares Outstanding11.41 M
Shares Owned By Insiders37.27 %
Shares Owned By Institutions42.66 %
Price To Book1.11 X
Price To Sales0.63 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft

Other Information on Investing in Rekah Stock

Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY